Skip to main content
. Author manuscript; available in PMC: 2017 Nov 15.
Published in final edited form as: Cell Rep. 2017 Oct 31;21(5):1169–1179. doi: 10.1016/j.celrep.2017.10.027

Fig. 1. SA-mutant VLPs require GAGS for binding to SFT gliosarcoma cells.

Fig. 1

Flow cytometry was used to measure the binding of wild-type and SA-mutant JCV and BKV VLPs to cells treated with heparinase I/III (orange), the sialyltransferase inhibitor 3Fax (green), or a combination of the two treatments (purple). MCV VLPs, which are known to require GAGs for cell attachment, were used as a control. Results are standardized to mock-treated SFT cells. One of two independent experiments is shown.